Former Sanofi-Pasteur MSD president joins board at Genticel
pharmafile | July 6, 2011 | Appointment | Research and Development | appointment, research and development
Genticel has named Dr Didier Hoch, former president of Sanofi-Pasteur MSD, to its supervisory board as conseil de surveillance.
Dr Hoch has over 25 years pharma experience, including ten years as president of Sanofi-Pasteur – MSD, the joint venture of the vaccine businesses of Sanofi and Merck & Co.
“Having Didier Hoch on our board is a real asset for Genticel as he brings a thorough understanding of the vaccine business at large and the HPV-cervical cancer field in particular,” said Thierry Hercend chairman of Genticel supervisory board.
The French clinical biopharmaceutical company develops human papillomavirus (HPV) vaccines and is currently conducting a large phase I clinical trial with its investigational candidate ProCervix.
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






